Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G
Laikon Hospital, Athens, Greece -
G Ital Dermatol Venereol. 2015 Apr;150(2):255-60.
Toll-like receptors (TLRs) are a category of receptors that recognize and activate their signaling pathways to defend against the pathogen factors. However, an alteration in the proper activation might occurr, resulting in the production of proinflammatory cytokines. This improper activation is the beginning of an autoimmune disease. The inhibition of the implicated receptors or their pathways may prevent the induction of autoimmunity. This paper describes in detail new therapeutic opportunities based on the alteration of the TLR activation for rheumatoid arthritis and systemic lupus erythematosus.
Toll样受体（TLRs）是一类能够识别并激活其信号通路以抵御病原体因子的受体。然而，可能会出现正常激活的改变，从而导致促炎细胞因子的产生。这种异常激活是自身免疫性疾病的开端。抑制相关受体或其信号通路可能会阻止自身免疫的诱导。本文详细描述了基于TLR激活改变针对类风湿性关节炎和系统性红斑狼疮的新治疗机会。
